title: Interleukin-17 targeted therapies in axial spondyloarthritis.
authors.affiliation: Department of Rheumatology, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, F-25030 Besançon, France.|Université de Franche-Comté, Boulevard Fleming, F-25030 Besançon, France.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001343:Autophagy / Q000235:genetics; D064806:Dysbiosis / Q000276:immunology / Q000628:therapy*; D020022:Genetic Predisposition to Disease; D015796:HLA-B27 Antigen / Q000235:genetics; D006801:Humans; D007167:Immunotherapy; D020381:Interleukin-17 / Q000276:immunology*; D053759:Interleukin-23 / Q000276:immunology; D007413:Intestinal Mucosa / Q000276:immunology* / Q000382:microbiology; D058990:Molecular Targeted Therapy; D013167:Spondylitis, Ankylosing / Q000276:immunology / Q000628:therapy*; D058504:Th17 Cells / Q000276:immunology*; D056811:Unfolded Protein Response / Q000235:genetics
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015796:HLA-B27 Antigen; D020381:Interleukin-17; D053759:Interleukin-23; C555450:secukinumab
keywords: IL-17; IL-23; ankylosing spondylitis; secukinumab; spondyloarthritis; treatment; ustekinumab